Apyx Medical - רווח החברה לפני מסים, ריבית ופחת APYX

Apyx Medical is expanding its business by developing helium-plasma systems for various types of surgery, which broadens its customer base. The EBITDA volume demonstrates resilient flows, with 0.00 serving as the current metric level. Leadership in a niche segment and the sale of consumables smooth out demand cyclicality, although intense competition from laser technologies necessitates significant investments in promotion.

Apyx Medical (APYX) monetizes its unique Renuvion helium plasma technology within the B2B aesthetic surgery segment, where business scale is determined by the volume of daily inflows. By analyzing EBITDA fluctuations, an investor can observe daily operating profit without reporting time lags, enabling a real-time assessment of cash flow resilience against market conditions and the determination of a fair support level for the asset's price.